» Articles » PMID: 36407451

Cardio Oncology: Digital Innovations, Precision Medicine and Health Equity

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The rapid emergence of cardio-oncology has resulted in a rapid growth of cardio-oncology programs, dedicated professional societies sections and committees, and multiple collaborative networks that emerged to amplify the access to care in this new subspecialty. However, most existing data, position statements and guidelines are limited by the lack of availability of large clinical trials to support these recommendations. Furthermore, there are significant challenges regarding proper access to cardio-oncology care and treatment, particularly in marginalized and minority populations. The emergence and evolution of personalized medicine, artificial intelligence (AI), and machine learning in medicine and in cardio-oncology provides an opportunity for a more targeted, personalized approach to cardiovascular complications of cancer treatment. The proper implementation of these new modalities may facilitate a more equitable approach to adequate and universal access to cardio-oncology care, improve health related outcomes, and enable health care systems to eliminate the digital divide. This article reviews and analyzes the current status on these important issues.

Citing Articles

Artificial Intelligence Applications in Cardio-Oncology: A Comprehensive Review.

Guha A, Shah V, Nahle T, Singh S, Kunhiraman H, Shehnaz F Curr Cardiol Rep. 2025; 27(1):56.

PMID: 39969610 DOI: 10.1007/s11886-025-02215-w.


The Digital Revolution in Medicine: Applications in Cardio-Oncology.

Echefu G, Batalik L, Lukan A, Shah R, Nain P, Guha A Curr Treat Options Cardiovasc Med. 2024; 27(1).

PMID: 39610711 PMC: 11600984. DOI: 10.1007/s11936-024-01059-x.


Cardio-oncology: chances and challenges.

Vinas-Mendieta A, Gallardo-Grajeda A, Lopez-Fernandez T Basic Res Cardiol. 2024; 120(1):3-9.

PMID: 39348001 DOI: 10.1007/s00395-024-01080-y.


Artificial Intelligence in Cardiology and Atherosclerosis in the Context of Precision Medicine: A Scoping Review.

Kolaszynska O, Lorkowski J Appl Bionics Biomech. 2024; 2024:2991243.

PMID: 38715681 PMC: 11074834. DOI: 10.1155/2024/2991243.


Does clinical research account for diversity in deploying digital health technologies?.

Coss N, Gaitan J, Adans-Dester C, Carruthers J, Fanarjian M, Sassano C NPJ Digit Med. 2023; 6(1):187.

PMID: 37816886 PMC: 10564850. DOI: 10.1038/s41746-023-00928-2.

References
1.
Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V . Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials. Circulation. 2019; 139(22):2594-2596. PMC: 8244729. DOI: 10.1161/CIRCULATIONAHA.118.039180. View

2.
Greenlee H, Iribarren C, Rana J, Cheng R, Nguyen-Huynh M, Rillamas-Sun E . Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022; 40(15):1647-1658. PMC: 9113215. DOI: 10.1200/JCO.21.01736. View

3.
Kwan J, Oikonomou E, Henry M, Sinusas A . Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Front Cardiovasc Med. 2022; 9:829553. PMC: 8964995. DOI: 10.3389/fcvm.2022.829553. View

4.
Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J . Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of.... Eur J Heart Fail. 2020; 22(9):1504-1524. DOI: 10.1002/ejhf.1957. View

5.
Hou Y, Zhou Y, Hussain M, Budd G, Tang W, Abraham J . Cardiac risk stratification in cancer patients: A longitudinal patient-patient network analysis. PLoS Med. 2021; 18(8):e1003736. PMC: 8366997. DOI: 10.1371/journal.pmed.1003736. View